This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

ThromboGenics' Founder Prof Desire Collen Retiring As Chairman

Stocks in this article: THR

LEUVEN, Belgium, December 6, 2013 /PRNewswire/ --

Dr Staf Van Reet appointed as new Chairman of the Board

ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, announces today that Prof Désiré Collen has decided to retire as Chairman and board member. Dr Staf Van Reet, currently a member of the ThromboGenics Board and a seasoned biopharma veteran, has been appointed Chairman of ThromboGenics.

Prof Collen, Founder and Chairman of ThromboGenics, said: " As the founder and a key member of the ThromboGenics team for more than 20 years, I ' ve decided it is time for me to take a step back and to stand down from my current role as ThromboGenics '  Chairman. I believe that this is an appropriate time to hand over to my successor.

" Recognizing a number of challenges, I believe that the Company has a clear strategy to optimize the  US  sales of JETREA ® and in the rest of the world via its partner Alcon. I remain confident that JETREA ® will find its way forward as part of a new standard of care for the treatment of symptomatic VMA/VMT, particularly for earlier stage patients. "       

Prof Collen, a world renowned scientist, has played an instrumental role in ThromboGenics' development and subsequent success since he founded the Company in 1991. During his tenure as CEO of ThromboGenics, the company started its research on JETREA ® (ocriplasmin) and advanced it through its early clinical development for the treatment of symptomatic vitreomacular adhesion (VMA)/ vitreomacular traction (VMT). He was appointed ThromboGenics' Chairman at the founding of the company.

Prof Collen has had an extensive and prominent career in drug development. Before the successful development of JETREA ®, Prof Collen led the research and development of tissue plasminogen activator (tPA), a key product for Genentech in the late 1980s and 1990s. This product revolutionized the treatment of acute myocardial infarction and stroke when it was introduced.

Prof Collen has been recognized as a leading figure in the life sciences industry. He has won numerous awards, including two recent lifetime achievement awards as recognition of his excellent services to the global industry. He has co-authored more than 650 scientific publications, and has co-invented over 20 issued patents and patent applications. During his career, he has proved a successful biotech entrepreneur and investor. In 1998 he set up Life Sciences Research Partners, which invests in emerging life sciences companies and promotes scientific research through grants, scholarships and related activities.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,672.60 -141.38 -0.79%
S&P 500 2,051.82 -11.33 -0.55%
NASDAQ 4,757.8790 +7.4820 0.16%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs